IM Cannabis Corp(IMCC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -62.81 | Insider Own | 34.4% | Shs Outstand | 1.6M | Perf Week | -15.5% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.1M | Perf Month | -58.08% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 0.63% | Short Float | 1.35% | Perf Quarter | -84.31% |
| Income | -0.01B | P/S | 0.03 | EPS this Y | - | Inst Trans | 12.84% | Short Ratio | 0.01 | Perf Half Y | -91.89% |
| Sales | 0.03B | P/B | - | EPS next 5Y | - | ROA | -54.47% | Short Interest | 0.01M | Perf YTD | -98.53% |
| Book/sh | -7.18 | P/C | 0.82 | EPS past 3/5Y | 74.93% 43.53% | ROE | -25089.74% | 52W High | -99.02% ($62.40) | Perf Year | -98.56% |
| Cash/sh | 0.75 | P/FCF | - | Sales past 3/5Y | -2.09% 27.02% | ROIC | - | 52W Low | 5.43% ($0.58) | Perf 3Y | -99.25% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -285.26% | Gross Margin | 12.57% | Volatility(W/M) | 12.43% 13.32% | Perf 5Y | -99.99% |
| Dividend TTM | - | EV/Sales | 0.29 | Sales Y/Y TTM | -11.91% | Oper. Margin | -25.87% | ATR (14) | 0.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.46 | EPS Q/Q | -396.75% | Profit Margin | -39.06% | RSI (14) | 29.22 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.56 | Sales Q/Q | -40.21% | SMA20 | -35.29% ($0.94) | Beta | 2.56 | Target Price | $180 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -64.76% ($1.73) | Rel Volume | 0.01 | Prev Close | $0.63 |
| Employees | 44 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -93.73% ($9.73) | Avg Volume(3M) | 2.69M | Price | $0.61 |
| IPO | 2020/5/20 | Option/Short | No/Yes | Trades | 129 | Volume | 18,824 | Change | -2.31% |
🍃 Medical cannabis platform. Operating in Israel and Germany. C4.7M revenue in 2025. 134% growth in Germany. Considering entry into the U.S. market.
Over the past 1 year, on the lower side
99% below its 1-year high.
Traded less than usual. That is 1% of its average volume.
IMCC has weak earnings and a weak balance sheet
Of every $100 in sales, $25.87 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3. Peers typically go for $174.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.6%.
Tap to view numbers
It ranks #83 of 83 in the industry
Based on market cap of $1M.
FAQ
What kind of company is IMCC?
IMCC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of IMCC?
The market cap of IMCC is approximately $1M, ranking 5,845 within its sector.
What is the 52-week high and low for IMCC?
IMCC has recorded a 52-week high of $62.40 and a low of $0.58.
